Colony-Stimulating Factors for Febrile Neutropenia during Cancer Therapy

被引:122
|
作者
Bennett, Charles L. [1 ,2 ,3 ,4 ]
Djulbegovic, Benjamin [5 ,6 ,7 ]
Norris, LeAnn B. [1 ,2 ,3 ,4 ]
Armitage, James O. [8 ]
机构
[1] Univ S Carolina, South Carolina Coll Pharm, South Carolina Ctr Econ Excellence Medicat Safety, Columbia, SC 29208 USA
[2] Univ S Carolina, South Carolina Coll Pharm, Southern Network Adverse React SONAR, Columbia, SC 29208 USA
[3] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA
[4] William Jennings Bryan Dorn Vet Affairs Med Ctr, Columbia, SC USA
[5] Univ S Florida, Morsani Coll Med, Ctr Evidence Based Med & Hlth Outcome Res, Clin & Translat Sci Inst,Dept Med, Tampa, FL USA
[6] H Lee Moffitt Canc Ctr & Res Inst, Dept Hematol, Tampa, FL USA
[7] H Lee Moffitt Canc Ctr & Res Inst, Dept Hlth Outcomes & Behav, Tampa, FL USA
[8] Univ Nebraska, Omaha Sch Med, Omaha, NE 68182 USA
来源
NEW ENGLAND JOURNAL OF MEDICINE | 2013年 / 368卷 / 12期
关键词
ACUTE MYELOID-LEUKEMIA; BONE-MARROW-TRANSPLANTATION; NON-HODGKIN-LYMPHOMA; CELL LUNG-CANCER; BREAST-CANCER; MYELODYSPLASTIC SYNDROME; CLINICAL-TRIALS; GROWTH-FACTORS; SOLID TUMORS; DOSE-DENSE;
D O I
10.1056/NEJMct1210890
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A 55-year-old, previously healthy woman received a diagnosis of diffuse large-B-cell lymphoma after the evaluation of an enlarged left axillary lymph node obtained on biopsy. She had been asymptomatic except for the presence of enlarged axillary lymph nodes, which she had found while bathing. She was referred to an oncologist, who performed a staging evaluation. A complete blood count and test results for liver and renal function and serum lactate dehydrogenase were normal. Positron-emission tomography and computed tomography (PET-CT) identified enlarged lymph nodes with abnormal uptake in the left axilla, mediastinum, and retroperitoneum. Results on bone marrow biopsy were normal. The patient's oncologist recommends treatment with six cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab (CHOP-R) at 21-day intervals. Is the administration of prophylactic granulocyte colony-stimulating factor (G-CSF) with the first cycle of chemotherapy indicated?
引用
收藏
页码:1131 / 1139
页数:9
相关论文
共 50 条
  • [31] Comparative effectiveness of colony-stimulating factors in febrile neutropenia prophylaxis: how results are affected by research design
    Henk, Henry J.
    Li, Xiaoyan
    Becker, Laura K.
    Xu, Hairong
    Gong, Qi
    Deeter, Robert G.
    Barron, Richard L.
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2015, 4 (01) : 37 - 50
  • [32] Clinical practice in febrile neutropenia risk assessment and granulocyte colony-stimulating factor primary prophylaxis of febrile neutropenia in Poland
    Wojtukiewicz, Marek
    Chmielowska, Ewa
    Filipczyk-Cisarz, Emilia
    Krzemieniecki, Krzysztof
    Lesniewski-Kmak, Krzysztof
    Litwiniuk, Maria M.
    Wieruszewska-Kowalczyk, Karolina
    Kosno-Kruszewska, Elzbieta
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2014, 18 (06): : 419 - 424
  • [33] Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia
    Advani, S. H.
    Achreckar, Suvarna
    Thomas, Dennis
    Krishnankutty, Binny
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2010, 31 (03) : 79 - 82
  • [34] Febrile neutropenia prophylaxis with short- and long-acting granulocyte colony-stimulating factors during treatment of solid tumours
    Kwinta, Lukasz
    ONCOLOGY IN CLINICAL PRACTICE, 2020, 16 (01): : 9 - 13
  • [35] Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer
    Matti S. Aapro
    Stephen Chaplin
    Paul Cornes
    Sebastian Howe
    Hartmut Link
    Natalia Koptelova
    Andrea Mehl
    Mario Di Palma
    Bridgette Kanz Schroader
    Robert Terkola
    Supportive Care in Cancer, 2023, 31
  • [36] Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients
    Puertolas, Isabel
    Frutos Perez-Surio, Alberto
    Aranzazu Alcacera, Maria
    Andres, Raquel
    del Transito Salvador, Maria
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 74 (03) : 315 - 321
  • [37] Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients
    Isabel Puértolas
    Alberto Frutos Pérez-Surio
    María Aránzazu Alcácera
    Raquel Andrés
    María del Tránsito Salvador
    European Journal of Clinical Pharmacology, 2018, 74 : 315 - 321
  • [38] Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer
    Aapro, Matti S.
    Chaplin, Stephen
    Cornes, Paul
    Howe, Sebastian
    Link, Hartmut
    Koptelova, Natalia
    Mehl, Andrea
    Di Palma, Mario
    Schroader, Bridgette Kanz
    Terkola, Robert
    SUPPORTIVE CARE IN CANCER, 2023, 31 (10)
  • [39] Febrile neutropenia and role of prophylactic granulocyte colony-stimulating factor in docetaxel and cyclophosphamide chemotherapy for breast cancer
    Yuri Kimura
    Shinsuke Sasada
    Akiko Emi
    Norio Masumoto
    Takayuki Kadoya
    Morihito Okada
    Supportive Care in Cancer, 2021, 29 : 3507 - 3512
  • [40] Febrile neutropenia and role of prophylactic granulocyte colony-stimulating factor in docetaxel and cyclophosphamide chemotherapy for breast cancer
    Kimura, Yuri
    Sasada, Shinsuke
    Emi, Akiko
    Masumoto, Norio
    Kadoya, Takayuki
    Okada, Morihito
    SUPPORTIVE CARE IN CANCER, 2021, 29 (07) : 3507 - 3512